Abstract:Objective:Th2 cell and cytokine IL-10 play an important role in the pathogenesis of membranous lupus nephropathy. Tacrolimus (FK506), an inhibitor of calcineurin, can inhibit the synthesis of IL-10 potently. In this study, we investigated the efficacy and adverse effects of tacrolimus in patients with membranous lupus nephropathy (WHO classification, class Ⅴ lupus nephritis). Methodology:A prospective preliminary study was conducted in 11 patients with membranous lupus nephritis proven by renal biopsy. In all the patients, the daily excretion of urinary protein exceeded 2.0 g, and the serum creatinine (SCr) was less than up-lower limit of normal range (110 μmol/L). All the patients received a regimen of FK506 combined with steroids. The starting dosage of FK506 was 0.1 mg/(kg·d), combined with prednisone at 0.6 mg/(kg·d). The dosage of prednisone was tapered after 4 weeks until a maintenance dosage of 10mg/d. Complete remission (CR) referred to daily urinary protein excretion reduced to 0.4g or below,no active urinary sediment (urinary RBC10×10 4/ml, no cast nor urinary WBC), serum albumin over 35g/L, SCr in normal range, and negativity of serum anti-dsDNA antibody. Partial remission (PR) referred to daily urinary protein excretion reduced to a range of 0.4-2.0 g and the reduction exceeded 50% or more of the baseline level, serum albumin equal or more than 30g/L, and SCr level in normal range. No-response (NR) referred to daily urinary protein excretion still exceeded 2.0g or the reduction less than 50% of the baseline value, serum albumin below 30g/L, or increment of SCr to more than 50% of the baseline value, or transformation to Class Ⅳ LN in repeat renal biopsy. Results:All the patients tolerated well to the regimen of FK506 for 3-15months, with nobody withdrew from the study. After treatment for 3 months, 2 of the 11 patients (18.2%) achieved complete remission, 5 patients (45.5%) achieved partial remission. In the 10 patients treated with FK506 for more than 6 months, 4 patients (40%) got CR and 4 patients got PR (40%) respectively. The median time to achieve CR/PR was 3 months (1-7months). In 7 of the 10 patients with hypoalbuminemia, serum albumin increased to normal range after treatment for 3 months. The titer of serum ANA and anti-dsDNA decreased,and the level of serum complement component increased significantly after treatment. Repeated renal biopsy in 8 patients (3 patients with CR, 3 with PR and 2 with NR) demonstrated that the activity index decreased from 4.8±2.38 to 2.25±1.28 (p0.05). There was no significant exacerbation of interstitial fibrosis. The adverse effects included temporary increased SCr level in 6 patients, and diarrhea, hypertension, herpes zoster each in 1 patient respectively. Conclusion:This preliminary study demonstrated that the regime of FK506 combined with low-dose prednisone is effective for patients with membranous lupus nephropathy.

Anti‐inflammatory and antioxidative actions of tacrolimus (FK506) on human microglial HMC3 cell line

Multiple Modes of Action of Tacrolimus (FK506) for Neuroprotective Action on Ischemic Damage after Transient Focal Cerebral Ischemia in Rats.

Tacrolimus Decreases Cognitive Function by Impairing Hippocampal Synaptic Balance: a Possible Role of Klotho

Tacrolimus (FK506) Attenuates Biphasic Cytochrome C Release and Bad Phosphorylation Following Transient Cerebral Ischemia in Mice

Tacrolimus (FK506) causes disease aggravation in models for inherited peripheral myelinopathies

Depletion of Microglia with PLX3397 Attenuates MK-801-induced Hyperactivity Associated with Regulating Inflammation-Related Genes in the Brain

Pimecrolimus protects neuron-like SH-SY5Y cells against anti-inflammatory and anti-oxidant effects of both microglial secretome and hydrogen peroxide

Repair of Neurological Function in Response to FK506 Through CaN/NFATc1 Pathway Following Traumatic Brain Injury in Rats

Effect of Kaempferol on Tacrolimus-Induced Nephrotoxicity and Calcineurin B1 Expression Level in Animal Model

Selective GSK3β Inhibition Mediates an Nrf2-Independent Anti-inflammatory Microglial Response

Lipopolysaccharide-Induced Microglial Neuroinflammation: Attenuation by FK866.

Effects of Tacrolimus (fk506)on Heat-Shock Proteins 70,Bcl-2 and Bax Expression in Nervous Tissue of Acrylamide-Induced Rat

Tacrolimus Combined with Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Trial

FK506 Attenuates the Inflammation in Rat Spinal Cord Injury by Inhibiting the Activation of NF-κB in Microglia Cells

A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis

Lactobacilli Cell-Free Supernatants Modulate Inflammation and Oxidative Stress in Human Microglia via NRF2-SOD1 Signaling

Plasticity of Treg and imbalance of Treg/Th17 cells in patients with systemic sclerosis modified by FK506

Restoration of HMGCS2-mediated ketogenesis alleviates tacrolimus-induced hepatic lipid metabolism disorder

Anti-Neuroinflammatory Effects of a Semi-Synthetic Isoorientin-Based Glycogen Synthase Kinase-3β Inhibitor in Lipopolysaccharide-Activated Microglial Cells

Proteomic Analysis of Hdac3 Selective Inhibitor in the Regulation of Inflammatory Response of Primary Microglia

A Prospective Preliminary Study of Tacrolimus (FK506) Combined with Low-Dose Prednisone in Patients with Membranous Lupus Nephropathy